18 04, 2018

What’s in a Name? For Some Psychiatrists, a Lot

By | 2018-04-19T09:16:18+00:00 April 18th, 2018|Brainscience Blogs, Brief Bulletins from the Field|0 Comments

The organization dedicated for decades to "Psychosomatic Medicine" will be rebranded as Consultation-Liaison Psychiatry. The name change, aimed in part at shedding the ambiguity around the word “psychosomatic” and better capturing the mission of consultation-liaison psychiatry, will be reflected across the group’s platforms. The tagline on the group’s journal, Psychosomatics, [...]

16 04, 2018

Anxiety and Depression May be Prevalent in Children with Comorbid Autism and ADHD

By | 2018-04-19T09:16:58+00:00 April 16th, 2018|Brainscience Blogs|0 Comments

Children with comorbid autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of anxiety and mood disorders, a cross-sectional analysis has shown. “Our study supports that anxiety and mood disorders, although highly prevalent in those with ASD alone, are even more prevalent in individuals who have [...]

16 04, 2018

Powerful Ketamine Nasal Spray Shows Promise in Quickly Treating Depressive Symptoms

By | 2018-04-19T09:17:31+00:00 April 16th, 2018|Brainscience Blogs|0 Comments

A more powerful ketamine (esketamine) nasal spray, combined with standard-of-care treatment, shows promise in quickly tamping-down depressive symptoms, according to results of a phase 2 study published April 16 in the American Journal of Psychiatry. In a study of 68 patients randomly assigned to either esketamine or placebo with standard-of-care treatment, [...]

10 04, 2018

Call For Papers — 2018 — 90-Day Fast Track Review

By | 2018-04-19T09:18:06+00:00 April 10th, 2018|Brainscience Blogs|0 Comments

For Immediate Release April 10, 2018 Los Angeles CA www.medworksmedia.com Psychopharmacology Bulletin DIGITAL ISSN: 2472-2448; PRINT ISSN: 0048-5764 From: Michael E. Thase, MD, Editor-in-Chief James La Rossa Jr., Editorial Director This is a unique call for scientific papers to be submitted for publication in Psychopharmacology Bulletin. Accepted manuscripts will be [...]

23 03, 2018

Psychopharmacology Bulletin Featured in EBSCO’s Latest Edition of New & Notable

By | 2018-03-23T15:32:55+00:00 March 23rd, 2018|Brainscience Blogs, MedWorks|0 Comments

We are excited to announce that MedWorks Media's flagship journal, Psychopharmacology Bulletin, has been featured in EBSCO's latest issue of New & Notable. MedWorks Media (Psychopharmacology Bulletin) has partnered with EBSCO Information Services for over 15 years. EBSCO Information Services provides a complete and optimized research solution comprised [...]

22 03, 2018

The Use of Gabapentin in Acute Alcohol Withdrawal

By | 2018-03-22T10:14:04+00:00 March 22nd, 2018|Brainscience Blogs|0 Comments

Gabapentin’s anxiolytic and sedative properties along with its overall safety profile suggest that it may be a viable adjuvant to lorazepam in the management of acute alcohol withdrawal. By Christopher Wilming, Mariah Alford, and Lynnette Klaus On average, the required benzodiazepine dosage was lower with concomitant use of gabapentin in [...]

19 03, 2018

First for Big Pharma: Novartis Strikes Deal with Canadian Company to Distribute Medical Marijuana Products

By | 2018-03-19T10:10:43+00:00 March 19th, 2018|Brainscience Blogs|0 Comments

In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products not only in its home country but also in Europe. Nanaimo, British Columbia-based Tilray announced today that it has a binding [...]

11 03, 2018

Lurasidone (Latuda) Gains FDA Approval for Bipolar Depression in Kids

By | 2018-03-11T08:25:45+00:00 March 11th, 2018|Brainscience Blogs|0 Comments

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the [...]

5 03, 2018

Viewpoint: Treating Bipolar Disorder Like Cancer

By | 2018-03-05T17:53:21+00:00 March 5th, 2018|Brainscience Blogs|0 Comments

In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors contributing to inadequate recognition and treatment of recurrent mood disorders, including unipolar depression and bipolar disorder. "This Viewpoint describes an [...]